Hansoh Pharmaceutical Group's (HKG:3692) HS-10561 capsules obtained China's National Medical Products Administration's approval for clinical trials to be tested for spontaneous hives, a Tuesday bourse filing said.
The capsules, Category 1 small molecule Bruton's tyrosine kinase inhibitor (BTKi) HS-10561, are jointly developed by the group and Guangzhou Lupeng Pharmaceutical.